Cardio Diagnostics Holdings Inc. - Common stock (CDIO)
0.4438
-0.0062 (-1.38%)
Cardio Diagnostics Holdings Inc. is a healthcare company focused on advancing personalized cardiovascular medicine through innovative diagnostic solutions
The company develops and commercializes cutting-edge technologies aimed at improving heart health management by offering comprehensive insights into individual cardiovascular risks. By leveraging advanced analytics and proprietary testing methodologies, Cardio Diagnostics seeks to empower healthcare providers and patients with actionable data to enhance decision-making and optimize treatment strategies for cardiovascular diseases. Their mission is to enhance patient outcomes and revolutionize the way cardiovascular health is understood and managed.
In a world where healthcare innovation is accelerating, companies leveraging artificial intelligence are leading the charge in transforming patient care, diagnostics, and therapeutic solutions. Their advancements in smart disinfection, AI-designed therapies, precision gene editing, and cardiovascular diagnostics are not only reshaping their industries but also unlocking tremendous growth potential. Here's how these cutting-edge companies are redefining the future of healthcare.
PALM BEACH, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Due to the expanding consumption of illicit drugs & alcohol across the globe the Drug Screening market is poised to grow substantially in the coming years. Drug abuse and alcohol consumption are growing worldwide. According to the World Drug Report 2023, in 2021, 1 in every 17 people aged 15–64 in the world had used a drug in the past 12 months. The number of users grew from 240 million in 2011 to 296 million in 2021 or 5.8% of the global population aged 15-64. This is a 23% increase, partly due to population growth. Other drugs like Cannabis the second most used drug, with an estimated 219 million users i.e. 4.3% of the global adult population in 2021. In 2021, according to the US Department of Transportation, National Highway Traffic Safety Administration (NHTSA), 13,384 people died in alcohol-impaired driving crashes, i.e. a 14% rise from last year. A report from MarketsAndMarkets projected that: “The global drug screening market, valued at US$7.7 billion in 2023, is forecasted to grow at a robust CAGR of 16.6%, reaching US$9.1 billion in 2024 and an impressive US$19.5 billion by 2029.North America dominates the drug screening market. This market is projected to reach USD 9.3 billion by 2029, at a CAGR of 16.4% during the forecast period. The expanding consumption of illicit drugs & alcohol will advance raise the development of drug screening products & services on the road, thereby driving the overall market growth.” Active companies in news today include: Intelligent Bio Solutions Inc. (NASDAQINBS), Cardio Diagnostics Holdings, Inc. NASDAQ: CDIONASDAQCDIO)(NASDAQ: BIAFNASDAQBIAF, Trinity Biotech plc (NASDAQ: TRIBNASDAQ), SOBR Safe, Inc. (NASDAQ: SOBRSOBR).
Cardio Diagnostics Holdings, Inc. (NASDAQCDIO), an AI-driven precision cardiovascular medicine company today announced that the Company’s PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from the Centers for Medicare & Medicaid Services (CMS). Following the preliminary pricing determination made by CMS in August 2024, CMS finalized the ‘gapfill’ pricing determination for both PrecisionCHD and Epi+Gen CHD. This decision will be effective for claims with dates of service on or after January 1, 2025, and will allow Medicare contractors to determine pricing for PrecisionCHD and Epi+Gen CHD based on actual cost data from Cardio Diagnostics. The Medicare contractors will report to CMS preliminary gapfill pricing for calendar year 2025 by April 1, 2025.
Cardio Diagnostics Holdings, Inc. (NASDAQCDIO), an AI-powered precision cardiovascular medicine company, today announced it will sponsor and exhibit at the Florida Association of ACOs (FLAACOs) 2024 Annual Fall Conference, taking place in Orlando, FL, from November 20-22, 2024. The conference, hosted at the JW Marriott Orlando Bonnet Creek, brings together healthcare leaders and organizations focused on advancing value-based care models nationwide.
Cardio Diagnostics Holdings, Inc. (NASDAQCDIO), an AI-driven precision cardiovascular medicine company today announced that the Company’s PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from the Centers for Medicare & Medicaid Services (CMS). This determination represents a crucial step toward securing Medicare reimbursement, enabling access to the Company’s affordable, innovative, and highly scalable blood tests aimed at improving the risk assessment, diagnosis, management and monitoring of coronary heart disease (CHD) for Medicare patients.
CDIO stock results show that Cardio Diagnostics Hldgs beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Cardio Diagnostics Holdings, Inc. (NASDAQCDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its redesigned website at CDIO.AI. This new site emphasizes the Company's AI-first approach and innovative scalable solutions for the prevention, detection and management of cardiovascular disease, which is the leading cause of death globally. This site also streamlines access to critical information and resources for investors, partners, patients, providers, and other key stakeholders.
Cardio Diagnostics Holdings, Inc. (NASDAQCDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company’s clinical blood test, Epi+Gen CHD is now available at Family Medicine Specialists’ (FMS) retail clinical location at the Meijer Supercenter in McHenry, Illinois.
Cardio Diagnostics Holdings, Inc. (NASDAQCDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum, taking place in Chicago, IL, from June 27-28, 2024. The Forum attracts senior executives from various healthcare sectors, including hospitals, health systems, health plans, and employer plans. The event is focused on enabling employers to build, launch, and optimize onsite clinical care facilities that are innovative and effective for their employees.
CDIO stock results show that Cardio Diagnostics Hldgs missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Mayumi Kitakata, a Tokyo resident, uses the AI-driven app CatsMe! to monitor the health of her aging cat, reflecting the growing trend of AI in pet healthcare.
